Skip to main content

Table 2 Correlation between changes in receptor expression and clinical factors

From: The effect of smoking on biological change of recurrent breast cancer

Parameters

Estrogen receptor

p value

Progesterone receptor

p value

HER2

p value

Negative conversion (n = 3)

The other (n = 47)

Negative Conversion (n = 15)

No change (n = 35)

Positive Conversion (n = 6)

No change (n = 44)

Age at operation (years old)

 ≤ 60

1 (33.3%)

25 (53.2%)

0.514

7 (46.7%)

19 (54.3%)

0.63

4 (66.7%)

22 (50.0%)

0.453

 > 60

2 (66.7%)

22 (46.8%)

8 (53.3%)

16 (45.7%)

 

2 (33.3%)

22 (50.0%)

Tumor size (mm)

 ≤ 21.8

1 (33.3%)

24 (51.1%)

0.561

10 (66.7%)

15 (42.9%)

0.128

4 (66.7%)

21 (47.7%)

0.394

 > 21.8

2 (66.7%)

23 (48.9%)

5 (33.3%)

20 (57.1%)

 

2 (33.3%)

23 (52.3%)

Lymph node metastasis

 Negative

2 (66.7%)

41 (87.2%)

0.33

12 (80.0%)

31 (88.6%)

0.434

6 (100.0%)

37 (84.1%)

0.302

 Positive

1 (33.3%)

6 (12.8%)

3 (20.0%)

4 (11.4%)

 

0 (0.0%)

7 (15.9%)

Ki67 of primary tumor

 ≤ 14%

2 (66.7%)

17 (36.2%)

0.301

5 (33.3%)

14 (40.0%)

0.664

1 (16.7%)

18 (40.9%)

0.26

 > 14%

1 (33.3%)

30 (63.8%)

10 (66.7%)

21 (60.0%)

5 (83.3%)

26 (59.1%)

Chemotherapy after surgery

 No

1 (33.3%)

36 (76.6%)

0.102

11 (73.3%)

26 (74.3%)

0.945

5 (83.3%)

32 (72.7%)

0.588

 Yes

2 (66.7%)

11 (23.4%)

4 (26.7%)

9 (25.7%)

1 (16.7%)

12 (27.3%)

Endocrine therapy after surgery

 No

1 (33.3%)

13 (27.7%)

0.836

0 (0.0%)

14 (40.0%)

0.003

2 (33.3%)

12 (27.3%)

0.762

 Yes

2 (66.7%)

34 (72.3%)

15 (100.0%)

21 (60.0%)

4 (66.7%)

32 (72.7%)

Radiation therapy after surgery

 No

1 (33.3%)

38 (80.9%)

0.056

10 (66.7%)

29 (82.9%)

0.213

5 (83.3%)

34 (77.3%)

0.743

 Yes

2 (66.7%)

9 (19.1%)

5 (33.3%)

6 (17.1%)

1 (16.7%)

10 (22.7%)

Trastuzumab after surgery

 No

3 (100.0%)

46 (97.9%)

0.804

15 (100.0%)

34 (97.1%)

0.518

6 (100.0%)

43 (97.7%)

0.716

 Yes

0 (0.0%)

1 (2.1%)

0 (0.0%)

1 (2.9%)

0 (0.0%)

1 (2.3%)

No-treatment after surgery

 No

3 (100.0%)

41 (87.2%)

0.519

15 (100.0%)

29 (82.9%)

0.091

5 (83.3%)

39 (88.6%)

0.715

 Yes

0 (0.0%)

6 (12.8%)

0 (0.0%)

6 (17.1%)

1 (16.7%)

5 (11.4%)

Age at recurrence (years old)

 ≤ 62

1 (33.3%)

25 (53.2%)

0.514

8 (53.3%)

18 (51.4%)

0.904

4 (66.7%)

22 (50.0%)

0.454

 > 62

2 (66.7%)

22 (46.8%)

7 (46.7%)

17 (48.6%)

2 (33.3%)

22 (50.0%)

Recurrence site biopsied

 Local, regional lymph node

2 (66.7%)

43 (91.5%)

0.25

14 (93.3%)

31 (88.6%)

0.458

6 (100.0%)

39 (88.6%)

0.715

 Distant metastasis

1 (33.3%)

4 (8.5%)

1 (6.7%)

4 (11.4%)

0 (0.0%)

5 (11.4%)

Change of ER in recurrence

 Negative conversion

–

–

–

2 (13.3%)

1 (2.9%)

0.159

0 (0.0%)

3 (6.8%)

0.519

 The other

–

–

13 (86.7%)

34 (97.1%)

6 (100.0%)

41 (93.2%)

Change of PgR in recurrence

 Negative conversion

2 (66.7%)

13 (27.7%)

0.159

–

–

–

3 (50.0%)

12 (27.3%)

0.264

 No change

1 (33.3%)

34 (72.3%)

–

–

3 (50.0%)

32 (72.7%)

Change of HER2 in recurrence

 Positive conversion

0 (0.0%)

6 (12.8%)

0.519

3 (20.0%)

3 (8.6%)

0.264

–

–

–

 No change

3 (100.0%)

41 (87.2%)

12 (80.0%)

34 (91.4%)

–

–

Disease free survival

 ≤ 792

2 (66.7%)

23 (48.9%)

0.561

8 (53.3%)

17 (48.6%)

0.764

3 (50.0%)

22 (50.0%)

1

 > 792

1 (33.3%)

24 (51.1%)

7 (46.7%)

18 (51.4%)

3 (50.0%)

22 (50.0%)

  1. HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PgR progesterone receptor